Madrigal Pharmaceuticals
MDGL
120 hedge funds and large institutions have $954M invested in Madrigal Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
26% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 34
15% more capital invested
Capital invested by funds: $831M → $954M (+$123M)
8% more funds holding
Funds holding: 111 → 120 (+9)
5.39% more ownership
Funds ownership: 62.49% → 67.88% (+5.4%)
92% less call options, than puts
Call options by funds: $2.31M | Put options by funds: $28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$12.8M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
+$11.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.2M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
+$7.27M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.22M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.26M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.63M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.59M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.28M |
MDGL Hedge Fund Activity: Q4 2019 in Review
120 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2019, worth a combined $954M — up 15% from $831M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MDGL positions and 16 closed out — a net gain of 9 holders — while 43 added to existing stakes and 34 trimmed.
The largest buyer was Laurion Capital Management, adding an estimated $12.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $9.22M.
- 120 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2019, up from 111 in Q3 2019.
- Funds reported $954M of Madrigal Pharmaceuticals stock for Q4 2019, up 15% quarter-over-quarter.
- 25 funds opened new Madrigal Pharmaceuticals positions in Q4 2019 and 16 closed out, a net change of +9 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2019 was Laurion Capital Management, an estimated $12.8M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2019 was T. Rowe Price Associates, an estimated $9.22M sold.
Based on aggregated 13F filings for Q4 2019.